Thromboprophylaxis in a patient with COVID‐19 and severe hemophilia A on emicizumab prophylaxis

COVID‐19 can be associated with coagulopathy (CAC, COVID‐19‐associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thromb Haemost
Autors principals: Rivas‐Pollmar, María Isabel, Álvarez‐Román, María Teresa, Butta‐Coll, Nora V., Martín Salces, Mónica, García‐Barcenilla, Sara, Jiménez‐Yuste, Victor
Format: Artigo
Idioma:Inglês
Publicat: International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2020
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307111/
https://ncbi.nlm.nih.gov/pubmed/32526092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14954
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars